Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Consolidated Net Income fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$53.2 million for Q3 2025, which was down 11.72% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Consolidated Net Income ranged from a high of $47.2 million in Q4 2024 and a low of -$53.2 million during Q3 2025.
  • Moreover, its 3-year median value for Consolidated Net Income was -$18.7 million (2023), whereas its average is -$19.0 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Consolidated Net Income crashed by 224.76% in 2023, and later skyrocketed by 561.54% in 2024.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' Consolidated Net Income stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then slumped by 144.58% to -$53.2 million in 2025.
  • Its last three reported values are -$53.2 million in Q3 2025, -$47.6 million for Q2 2025, and -$37.2 million during Q1 2025.